Health Condition 1: null- vitiligo
Conditions
Interventions
Intervention1: H-009: Homeopathy pills 30c potency
for three months. Dose- 6 pills
three times daily.
Intervention2: Arsenic-sulphuricum-flavum: Homeopathy pills 30c potency for three months. Dose- 6
Sponsors
Homeopathy India Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: Patients with focal vitiligo. Focal vitiligo This type is characterized by one or more lesions in single area. Patient is willing and able to give written informed consent Vitiligo stable since 3 months, that is, there should have been no increase of spots in number or size, during last three months. Patient having vitiligo spots, size up less than 15cm x 15cm.
Exclusion criteria
Exclusion criteria: Patient having extensive vitiligo, bilateral symmetrical or having onlymuco-cutaneus junction (such as lips, genitals, finger-tips, etc.) affection. Any form of systemic, injectable or topical treatment (conventional, homeopathic, Ayurvedic, Cuben, Phototheraphy, surgical, laser, etc.) during the last 2 months Patients having uncontrolled or untreated under active Thyroid. (To be ruled out by TSH study.) Patient who are on or have consumed in last three months any anti-cancer (conventional) medication. Women of childbearing age who had tested positive for pregnancy, or who do not use acceptable contraceptive method, or do not agree to practice reliable contraception during the study. Current Participation or participation in last 3 months period, in any clinical trial. Any finding of clinical observation (anamnesis and physical exam) laboratory abnormality, disease (for example, liver, cardiovascular system, lung) or therapy that, in opinion of the investigator may endanger the subject or interfere with the endpoints of study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate ability of potentized preparation H-009 and Arsenic-sulphuricum-flavum in stimulating pigmentation on vitiligo patches using 30c and 50c potencies.Timepoint: Efficacy end points at week 6 and week 12. | — |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of pigmentation produced by the medicine on vitiligo patches, Comparative study in terms of improvement in vitiligo patches, Change in Vital signs Laboratory evaluations (blood chemistry, hematology, urinalysis) Electrocardiogram (ECG), to examine toxic effects of the IP, if any. Timepoint: Efficacy end points at week 6 and week 12 and safety at week 12. | — |
Countries
India
Contacts
Public ContactDr Rajesh Shah
Life Force Center
Outcome results
None listed